Verastem, Inc., , a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the filing of orphan drug designation for VS-6063. Verastem is seeking orphan drug designation in the US and the EU for the use of VS-6063 in mesothelioma.
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130214005371&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130214005371&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment